Evaluation of XmAb541 in Patients with Advanced Solid Tumors: A Phase I Clinical Trial

The primary objective of this study is to evaluate the efficacy of the investigational drug XmAb541 in patients diagnosed with advanced solid tumors. Assessing the therapeutic response in this population is clinically relevant to determine the potential for improved survival outcomes or tumor regression in patients with progressive malignancy.

This clinical trial involves 182 patients diagnosed with advanced solid tumors. The study population includes both male and female participants. Based on the provided age range codes, the subjects are categorized within specific developmental age groups. The sponsor has identified the study population as including vulnerable individuals.

This Phase 1 clinical trial utilizes a research design to evaluate the investigational drug xmAb541 in individuals diagnosed with advanced solid tumors. The study protocol involves a sequence of clinical assessments beginning with a screening visit to determine eligibility. Following enrollment, participants undergo periodic follow-up visits to monitor clinical developments and safety parameters. The procedure concludes with an end-of-study visit. The total duration of the trial, spanning from recruitment to completion, is estimated to last approximately 24 months. Participation may be discontinued prior to the scheduled conclusion based on specific clinical criteria or safety requirements.

Efficacy assessment in this study involves the evaluation of therapeutic responses in patients with advanced solid tumors. The primary focus is directed toward determining the clinical impact of the intervention within the context of a Phase 1 clinical trial.